Investing.com - Avadel Pharma (NASDAQ: AVDL) reported third quarter EPS of $-0.410, $0.03 worse than the analyst estimate of $-0.380. Revenue for the quarter came in at $7.01M versus the consensus estimate of $5.12M.
Avadel Pharma's stock price closed at $10.380. It is down -28.660% in the last 3 months and up 81.150% in the last 12 months.
Avadel Pharma saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Avadel Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Avadel Pharma's Financial Health score is "fair performance".
Check out Avadel Pharma's recent earnings performance, and Avadel Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar